Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight

The Dravet syndrome market is poised for steady growth, driven by increasing disease awareness, earlier genetic diagnosis, and the expanding adoption of targeted anti-seizure therapies. The introduction of innovative treatments, including Zorevunersen (STK-001) (Stoke Therapeutics and Biogen), Bexicaserin (LP352) (Lundbeck), Clemizole Hydrochloride (EPX-100) (Harmony Biosciences), ETX101 (Encoded Therapeutics), and others, is expected to improve patient outcomes and expand the treatment landscape.

New York, USA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight

The Dravet syndrome market is poised for steady growth, driven by increasing disease awareness, earlier genetic diagnosis, and the expanding adoption of targeted anti-seizure therapies. The introduction of innovative treatments, including Zorevunersen (STK-001) (Stoke Therapeutics and Biogen), Bexicaserin (LP352) (Lundbeck), Clemizole Hydrochloride (EPX-100) (Harmony Biosciences), ETX101 (Encoded Therapeutics), and others, is expected to improve patient outcomes and expand the treatment landscape.

Recently published Dravet Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Dravet syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Dravet Syndrome Market Summary

• The total Dravet syndrome treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest Dravet syndrome treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The total diagnosed prevalence of Dravet syndrome in the 7MM comprised ~25,600 cases in 2025.
• Key Dravet syndrome companies, including Stoke Therapeutics, Biogen, Lundbeck, Harmony Biosciences, Encoded Therapeutics, Bright Minds Bio, Bloom Science, Neuroene Therapeutics, Ionis, Emugen Therapeutics, Regel Therapeutics, and others, are actively working on innovative Dravet syndrome drugs. 
• Some of the key Dravet syndrome therapies in clinical trials include Zorevunersen (STK-001), Bexicaserin (LP352), Clemizole Hydrochloride (EPX-100), ETX101, BMB-101, BL-001, NT102, ION337, EMU003, RT101, and others. These novel Dravet syndrome therapies are anticipated to enter the Dravet syndrome market in the forecast period and are expected to change the market.

Discover Dravet syndrome latest research 2026 @ https://www.delveinsight.com/report-store/dravet-syndrome-market

Key Factors Driving the Growth of the Dravet Syndrome Market 

• Rising Dravet Syndrome Prevalence: The increasing prevalence of Dravet syndrome, particularly among children aged ≤16 years, is a key driver of market growth. In the US, there were approximately ~22,600 diagnosed prevalent cases in 2025, which are expected to increase further by 2036, driven by improved diagnosis, greater awareness, and advancements in genetic testing.
• Advancements in Targeted Therapies: The availability of disease-specific therapies and the development of novel precision medicines are transforming the treatment landscape. Innovative approaches, including gene-targeted and RNA-based therapies, are expected to improve seizure control and address underlying disease mechanisms, driving market expansion.
• Robust Pipeline and Ongoing Clinical Research: A strong clinical pipeline featuring investigational therapies such as Zorevunersen (STK-001) (Stoke Therapeutics and Biogen), Bexicaserin (LP352) (Lundbeck), Clemizole Hydrochloride (EPX-100) (Harmony Biosciences), ETX101 (Encoded Therapeutics), and others, is expected to diversify treatment options. Continuous research and late-stage clinical trials are increasing the likelihood of new product approvals, supporting long-term market growth.

Aparna Thakur, Project Manager of Forecasting at DelveInsight, said that gene therapies such as Encoded Therapeutics’ ETX101 and antisense oligonucleotides such as Stoke Therapeutics and Biogen’s Zorevunersen (STK-001) are expected to drive the next wave of innovation with potential disease-modifying benefits, while serotonergic agents and established anti-seizure medications will continue to support near-term market growth.

Dravet Syndrome Market Analysis

• Dravet syndrome is primarily treated with combination anti-seizure therapies, including fenfluramine, cannabidiol, stiripentol, valproate, and clobazam, while sodium channel blockers are generally avoided due to their potential to worsen seizures. 
• Comprehensive disease management also involves minimizing seizure triggers, administering rescue therapies for status epilepticus, and providing ongoing developmental, behavioral, and safety-related support.
• Approved treatment options for Dravet syndrome currently include EPIDIOLEX (Jazz Pharmaceuticals), DIACOMIT (Biocodex), FINTEPLA (UCB/Zogenix), along with other available therapies that help manage the condition.
• The late-stage therapeutic pipeline for Dravet syndrome features promising candidates such as zorevunersen (STK-001) (Stoke Therapeutics/Biogen), ETX101 (Encoded Therapeutics), bexicaserin (LP352) (Lundbeck), among other investigational therapies under clinical development.

Learn more about the Dravet syndrome therapeutics market @ US Dravet Syndrome Market

Dravet Syndrome Competitive Landscape

Some of the Dravet syndrome drugs under development include Zorevunersen (STK-001) (Stoke Therapeutics and Biogen), Bexicaserin (LP352) (Lundbeck), Clemizole Hydrochloride (EPX-100) (Harmony Biosciences), ETX101 (Encoded Therapeutics), BMB-101 (Bright Minds Bio), BL-001 (Bloom Science), NT102 (Neuroene Therapeutics), ION337 (Ionis), EMU003 (Emugen Therapeutics), RT101 (Regel Therapeutics), and others.

Stoke Therapeutics and Biogen’s Zorevunersen (STK-001) is an investigational therapy being studied in ongoing clinical trials for the treatment of Dravet syndrome. The therapy is intended to increase NaV1.1 protein production by utilizing the healthy (wild-type) copy of the SCN1A gene, aiming to restore normal physiological NaV1.1 levels. This approach has the potential to reduce seizure frequency while also addressing major non-seizure complications associated with the disorder. The therapy has received both Rare Pediatric Disease Designation and Breakthrough Therapy Designation from the FDA for patients with Dravet syndrome carrying confirmed SCN1A mutations that are not linked to gain-of-function variants.

Encoded Therapeutics is advancing ETX101, an investigational, one-time gene regulation therapy designed to modify the course of SCN1A-positive Dravet syndrome. As the company's lead candidate, ETX101 targets the underlying genetic cause of the disease by selectively regulating gene expression in affected cells. The therapy is being developed to improve not only seizure control but also the cognitive, behavioral, developmental, and motor impairments associated with Dravet syndrome. According to the company's development pipeline, ETX101 is currently in the early stages of clinical evaluation.

The anticipated launch of these emerging Dravet syndrome therapies are poised to transform the Dravet syndrome market landscape in the coming years. As these cutting-edge Dravet syndrome therapies continue to mature and gain regulatory approval, they are expected to reshape the Dravet syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about the Dravet syndrome treatment market, visit @ Dravet Syndrome Therapeutic Market

Recent Developments in the Dravet Syndrome Market

• In July 2026, Ionis Pharmaceuticals announced the dosing of the first patient in the Phase I/II ASCEND study, evaluating its investigational RNA-targeted therapy, ION337, for the treatment of Dravet syndrome, a rare and severe neurological disorder.
• In June 2026, Stoke Therapeutics, Inc. announced the completion of enrollment of 162 patients in the Phase 3 EMPEROR trial evaluating zorevunersen. Following completion of enrollment, the company plans to begin a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027.
• In April 2026, Jazz Pharmaceuticals presented research on EPIDIOLEX (cannabidiol) Oral Solution for Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting. 
• In March 2026, Stoke Therapeutics and Biogen reported in The New England Journal of Medicine that their investigational RNA therapy zorevunersen showed early evidence of potential disease modification in Dravet syndrome, based on Phase I/IIa and ongoing extension study results. 
• In March 2026, Encoded Therapeutics announced the successful completion of its Initial Comprehensive Multidisciplinary Regenerative Medicine Advanced Therapy (RMAT) meeting with the US Food and Drug Administration (FDA), and alignment on the pivotal study design supporting the company’s planned BLA submission for ETX101, an AAV9-based gene regulation therapy designed as a one-time, disease-modifying treatment for SCN1A+ Dravet syndrome.
• In January 2026, Encoded Therapeutics announced that the US FDA had granted Breakthrough Therapy Designation to ETX101 for the treatment of SCN1A+ Dravet syndrome.

Dravet Syndrome Epidemiology Segmentation

The Dravet syndrome epidemiology section provides insights into the historical and current Dravet syndrome patient pool and forecasted trends for the leading markets. In the 7MM, the US accounted for the highest share (~50%) of diagnosed prevalent cases of Dravet syndrome in 2025. 

The Dravet syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

• Total Diagnosed Prevalent Cases of Dravet Syndrome 
• Mutation-specific Diagnosed Prevalent Cases of Dravet Syndrome 
• Age-specific Diagnosed Prevalent Cases of Dravet Syndrome 
• Gender-specific Diagnosed Prevalent Cases of Dravet Syndrome

Download the report to understand the future of Dravet syndrome treatment @ Dravet Syndrome Treatment Options

Dravet Syndrome Market Report Metrics	Details
Study Period	2022–2036
Dravet Syndrome Market Report Coverage	7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Dravet Syndrome Market Epidemiology Segmentation	Total Diagnosed Prevalent Cases of Dravet Syndrome, Mutation-specific Diagnosed Prevalent Cases of Dravet Syndrome, Age-specific Diagnosed Prevalent Cases of Dravet Syndrome, and Gender-specific Diagnosed Prevalent Cases of Dravet Syndrome
Key Dravet Syndrome Companies	Stoke Therapeutics, Biogen, Lundbeck, Harmony Biosciences, Encoded Therapeutics, Bright Minds Bio, Bloom Science, Neuroene Therapeutics, Ionis, Emugen Therapeutics, Regel Therapeutics, Jazz Pharmaceuticals, UCB, Zogenix, BIOCODEX, and others
Key Dravet Syndrome Therapies	Zorevunersen (STK-001), Bexicaserin (LP352), Clemizole Hydrochloride (EPX-100), ETX101, BMB-101, BL-001, NT102, ION337, EMU003, RT101, EPIDIOLEX/EPIDYOLEX, FINTEPLA, DIACOMIT, and others

Scope of the Dravet Syndrome Market Report

• Dravet Syndrome Patient Population Forecast
• Dravet Syndrome Therapeutics Market Size
• Dravet Syndrome Pipeline Analysis
• Dravet Syndrome Market Size and Trends
• Dravet Syndrome Market Opportunity
• Dravet Syndrome Market Unmet Needs
• KOL’s Views on Dravet Syndrome
• Dravet Syndrome Market Access and Reimbursement

Discover more about next-generation Dravet syndrome drugs @ Dravet Syndrome Clinical Trials

Table of Contents

1	Dravet Syndrome Market Key Insights
2	Dravet Syndrome Market Report Introduction
3	Executive Summary
4	Key Events
5	Epidemiology and Market Forecast Methodology
6	Dravet Syndrome Market Overview at a Glance
6.1	Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2	Market Share (%) Distribution of Dravet Syndrome by Therapies in the 7MM, in 2025
6.3	Market Share (%) Distribution of Dravet Syndrome by Therapies in the 7MM, in 2036
7	Disease Background and Overview of Dravet Syndrome
7.1	Introduction
7.2	Types
7.3	Symptoms
7.4	Causes
7.5	Pathophysiology
7.6	Diagnosis
7.7	Treatment
8	Treatment Guidelines for Dravet Syndrome
9	Epidemiology and Patient Population of Dravet Syndrome
9.1	Key Findings
9.2	Assumptions and Rationale
9.3	Total Diagnosed Prevalent Cases of Dravet Syndrome in the 7MM
9.4	The United States
9.4.1	Total Diagnosed Prevalent Cases of Dravet Syndrome in the United States
9.4.2	Mutation-specific Diagnosed Prevalent Cases of Dravet Syndrome in the United States
9.4.3	Age-specific Diagnosed Prevalent Cases of Dravet Syndrome in the United States
9.4.4	Gender-specific Diagnosed Prevalent Cases of Dravet Syndrome in the United States
9.5	EU4 and the UK
9.6	Japan
10	Patient Journey of Dravet Syndrome
11	Marketed Dravet Syndrome Therapies
11.1	Marketed Competitive Landscape of Dravet Syndrome
11.2	Cannabidiol (EPIDIOLEX/EPIDYOLEX): Jazz Pharmaceuticals
11.2.1	Drug Description
11.2.2	Regulatory Milestones
11.2.3	Other Developmental Activities
11.2.4	Summary of Pivotal Trials
11.2.5	Clinical Development
11.2.5.1	Clinical Trial Information
11.2.6	Analyst’s Views
11.3	Fenfluramin (FINTEPLA): UCB/Zogenix
List to be continued….
12	Emerging Dravet Syndrome Therapies
12.1	Emerging Competitive Landscape of Dravet Syndrome
12.2	Zorevunersen (STK-001): Stoke Therapeutics and Biogen
12.2.1	Drug Description
12.2.2	Other Developmental Activities
12.2.3	Clinical Development
12.2.3.1	Clinical Trials Information
12.2.4	Safety and Efficacy
12.2.5	Analyst’s Views
12.3	Bexicaserin (LP352): Longboard Pharmaceuticals
List to be continued….
13	Dravet Syndrome Market : 7MM Analysis
13.1	Key Findings
13.2	Market Outlook of Dravet Syndrome
13.3	Key Dravet Syndrome Market Forecast Assumptions
13.4	Conjoint Analysis of Dravet Syndrome
13.5	Total Market Size of Dravet Syndrome in the 7MM
13.6	Total Market Size of Dravet Syndrome by Therapies in the 7MM
13.7	The United States Dravet Syndrome Market
13.7.1	Total Market Size of Dravet Syndrome in the United States
13.7.2	Total Market Size of Dravet Syndrome by Therapies in the United States
13.8	EU4 and the UK Dravet Syndrome Market
13.9	Japan Dravet Syndrome Market
14	Unmet Needs of Dravet Syndrome
15	SWOT Analysis of Dravet Syndrome
16	KOL Views of Dravet Syndrome
17	Market Access and Reimbursement of Dravet Syndrome
17.1	The United States
17.2	EU4 and the UK
17.3	Japan
17.4	Summary and comparison of Market Access and Pricing Policy Developments in 2025
17.5	Market Access and Reimbursement of Dravet Syndrome Therapies
18	Bibliography
19	Dravet Syndrome Market Report Methodology

Related Reports

Dravet Syndrome Clinical Trial Analysis 

Dravet Syndrome Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Dravet syndrome companies, including Hinova Pharmaceuticals, Lantheus, Janux Therapeutics, Tagworks Pharmaceuticals, AstraZeneca, Xencor, Cardiff Oncology, Madison Vaccines, Bayer, Olema Oncology, Eli Lilly and Company, Curium, Pfizer, Regeneron Pharmaceuticals, PendreaBio, Momotaro-Gene, Norroy Bioscience, Orion Corporation, Epizyme, Barinthus Biotherapeutics, Twinpig Biolab, Oxford Vacmedix, Roche, ImaginAb, Halda THERAPEUTICS, Novartis, Kyinno Biotechnology, and others.

Developmental and Epileptic Encephalopathies Market

Developmental and Epileptic Encephalopathies Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DEE companies including Ultragenyx Pharmaceutical, Oak Hill Bio, Roche, Praxis Precision Medicines, Longboard Pharmaceuticals (acquired by Lundbeck), Stoke Therapeutics, Praxis Precision Medicines, Harmony Biosciences, SK Life Science (Subsidiary of SK Biopharmaceuticals), Ionis Pharmaceuticals, Encoded Therapeutics, Cerecin Neurosciences, Oils4Cure, Bright Minds Biosciences, and others.

Developmental and Epileptic Encephalopathies Clinical Trial Analysis 

Developmental and Epileptic Encephalopathies Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DEE companies, including Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies,  and others.

Epilepsy Market

Epilepsy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies including Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.

Lennox–Gastaut Syndrome Market

Lennox–Gastaut Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key LGS companies, including GlaxoSmithKline, Meda Pharmaceuticals, Roche, Lundbeck, Greenwich Biosciences, Janssen Pharmaceuticals, Eisai, Zogenix, Takeda, Ovid Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679